Comparison of PR3-ANCA specific assay performance for the diagnosis of granulomatosis with polyangiitis (Wegener's)

Clinical Chemistry and Laboratory Medicine

Volumn 51, Issue 11, 2013, Pages 2141-2149

  Radice, Antonella ^a   Bianchi, Laura ^a   Maggiore, Umberto ^b   Vaglio, Augusto ^b   Sinico, Renato A ^a  

^a SAN CARLO BORROMEO HOSPITAL   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

antineutrophil cytoplasmic autoantibodies (ANCA); granulomatosis with polyangiitis (GPA); proteinase 3 (PR3)

Indexed keywords

MYELOBLASTIN; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ADULT; AESKULISA PR3 SENSITIVE ASSAY; AGED; ANALYTICAL EQUIPMENT; ANCA ASSOCIATED VASCULITIS; ANTI PR3 ASSAY; ANTI PR3 CAPTURE ELISA; ANTI PR3 HN HR ELISA; ANTI PR3 HS; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DIRECT PR3 ELIA ASSAY; ELIA PR3 ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOASSAY; IMMUNOFLUORESCENCE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MICROSCOPIC POLYANGIITIS; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SMALL VESSEL VASCULITIS; WEGENER GRANULOMATOSIS; WEISLAB CAPTURE PR3 ANCA ASSAY; ZENIT RA PR3 ANCA ASSAY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LUMINESCENT MEASUREMENTS; MALE; MIDDLE AGED; MYELOBLASTIN; ROC CURVE; WEGENER GRANULOMATOSIS; YOUNG ADULT;

EID: 84886673526     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2013-0308     Document Type: Article

References (41)

1. Savige J, Davies D, Falk RJ, Jennette JC, Wiik A. Antineutrophil cytoplasmic antibodies and associated diseases: A review of the clinical and laboratory features. Kidney Int 2000;57:846-62
2. Radice A, Sinico RA. Antineutrophil cytoplasmic antibodies (ANCA). Autoimmunity 2005;38:93-103
3. Sinico RA, Di Toma L, Maggiore U, Bottero P, Radice A, Tosoni C, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in churg-strauss syndrome. Arthritis Rheum 2005;52:2926-35
4. Sinico RA, Radice A, Pozzi C, Ferrario F, Arrigo G. Diagnostic significance and antigen specificity of antineutrophil cytoplasmic antibodies in renal disease. A prospective multicentric study. Nephrol Dial Transplant 1994;9:505-10
5. Boomsma MM, Stegeman CA, van der Leij MJ, Oost W, Hermans J, Kallenberg CG, et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels. Arthritis Rheum 2000;43:2025-33
6. Kerr GS, Fleisher TA, Hallahan CW, Leavitt RY, Fauci AS, Hoffman GS. Limited prognostic value of changes in antineutrophil cytoplasm antibody titer in patients with Wegener's granulomatosis. Arthritis Rheum 1993;36:365-71
7. Girard T, Mahr A, Noel LH, Cordier JF, Lesavre P, Andr è MH. Are antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener's granulomatosis? A prospective study. Rheumatology (Oxford) 2001;40:147-51
8. Han WK, Choi HK, Roth RM, McCluskey RT, Niles JL. Serial ANCA titers: Useful tool for prevention of relapses in ANCA-Associated vasculitis. Kidney Int 2003;63:1079-85
9. Savige J, Gillis D, Benson E, Davies D, Esnault V, Falk R, et al. International consensus statement on testing and reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). Am J Clin Pathol 1999;111:507-13
10. Savige J, Dimech W, Fritzler M, Goeken J, Hagen EC, Jennette JC, et al. For the international group for consensus statement on testing and reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). Addendum to the international consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies. Am J Clin Pathol 2003;120:312-8
11. Wiik A. Delineation of a standard procedure for indirect immunofluorescence detection of ANCA. APMIS 1989;6:12-3
12. Radice A, Vecchi M, Bianchi MB, Sinico RA. Contribution of immunofluorescence to the identification and characterization of anti-neutrophil cytoplasmic autoantibodies. The role of different fixatives. Clin Exp Rheumatol 2000;18:707-12
13. Goldschmeding R, van der Schoot CE, ten Bokkel Huinink D, Hack CE, van den Ende ME, Kallenberg CG. Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils. J Clin Invest 1989;84:1577-87
14. Radice A, Sabadini E, Sinico RA. Antineutrophil cytoplasmic autoantibodies with specificity for proteinase 3. In: Shoenfeld Y, Gershwin E, Meroni PL, editors. Autoantibodies. Amsterdam: Elsevier, 2006
15. Merkel PA, Polisson RP, Chang YC, Skates SJ, Niles JL. Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease. Ann Intern Med 1997;126:866-73
16. Jennette JC, Wilkman AS, Falk RJ. Diagnostic predictive value of ANCA serology. Kidney Int 1998;53:796-8
17. Brenner H, Gefeller O. Variation of sensitivity, specificity, likelihood ratios and predictive values with disease prevalence. Stat Med 1997;16:981-91
18. Wang G, Csernok E, De Groot K, Gross WL. Comparison of eight commercial kits for quantitation of antineutrophil cytoplasmic antibodies (ANCA). J Immunol Methods 1997;208:203-11
19. Csernok E, Ahlquist D, Ullrich S, Gross WL. A critical evaluation of commercial immunoassays for antineutrophil cytoplasmic antibodies directed against proteinase 3 and myeloperoxidase in Wegener's granulomatosis and microscopic polyangiitis. Rheumatology (Oxford) 2002;41:1313-7
20. Holle JU, Hellmich B, Backes M, Gross WL, Csernok E. Variations in performance characteristics of commercial enzyme immunoassay kits for detection of antineutrophil cytoplasmic antibodies: What is the optimal cut off? Ann Rheum Dis 2005;64:1773-9
21. Sommarin Y, Rasmussen N, Wieslander J. Characterization of monoclonal antibodies to proteinase 3 and application in the study of epitopes for classical anti-neutrophil cytoplasm antibodies. Exp Nephrol 1995;3:249-56
22. Erdbrugger U, Hellmark T, Bunch DO, Alcorta DA, Jennette JC, Falk RJ, et al. Mapping of myeloperoxidase epitopes recognized by MPO-ANCA using human-mouse MPO chimers. Kidney Int 2006;69:1799-805
23. Westman KW, Selga D, Bygren P, Segelmark M, Baslund B, Wiik A, et al. Clinical evaluation of a capture ELISA for detection of proteinase 3 antineutrophil cytoplasmic antibody. Kidney Int 1998;53:1230-6
24. Csernok E, Holle J, Hellmich B, Willem J, Tervaert C, Kallenberg CG, et al. Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener's granulomatosis: First results from a multicentre study. Rheumatology (Oxford) 2004;43:174-80
25. Hellmich B, Csernok E, Fredenhagen G, Gross WL. A novel high sensitivity ELISA for detection of antineutrophil cytoplasm antibodies against proteinase-3. Clin Exp Rheumatol 2007;25:1-5
26. Radice A, Bianchi L, Palumbo A, Sinico RA. Clinical evaluation of the new AeskulisaPR3sensitiv assay for the diagnosis of Wegener granulomatosis. APMIS 2009;117(s127):180
27. Damoiseaux J, Dänrich C, Rosemann A, Probst C, Komorowski L, Stegeman CA, et al. A novel enzyme-linked immunosorbent assay using a mixture of human native and recombinant proteinase-3 significantly improves the diagnostic potential for antineutrophil cytoplasmic antibodyassociated vasculitis. Ann Rheum Dis 2009;68:228-33
28. Radice A, Bianchi L, Palumbo A, Sinico RA. A novel PR3-ANCA ELISA with a mixture of human purified and recombinant PR3 as solid phase antigen. In: Conrad K, Chan EK, Fritzler MJ, Humbel RL, von Landenberg P, Shoenfeld Y, editors. From pathogenesis to therapy of autoimmune diseases. PABST Science Publishers 2009;6:383-5
29. Fries JF, Hunder GG, Bloch DA, Michel BA, Arend WP, Calabrese LH, et al. The American College of Rheumatology, criteria for the classification of vasculitis. Summary. Arthritis Rheum 1990;33:1135-6
30. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187-92
31. Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, et al. Development and validation of a consensus methodology for the classification of the ANCA-Associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007;66:222-7
32. Ruperto N. For the Paediatric Rheumatology International Trials Organisation (PRINTO). Classification criteria and diagnostic tests for vasculitides. J Rheumatol 2012;39:1503-5
33. Sinico RA, Pozzi C, Radice A, Tincani A, Li Vecchi M, Rota S, et al. Clinical significance of antineutrophil cytoplasmic autoantibodies with specificity for lactoferrin in renal diseases. Am J Kidney Dis 1993;22:253-60
34. Obuchowski N, McClish D. Sample size determination for diagnostic accuracy studies involving binormal ROC curve indices. Stat Med 1997;16:1529-42
35. Li J, Fine J. On sample size for sensitivity and specificity in prospective diagnostic accuracy studies. Stat Med 2004;23:2537-50
36. Stata Base Reference Manual Release 11, Vol. 3. Stata Press Publication, StataCorp, College Station, TX, USA, 2009: 1595-615
37. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristics curve: A non parametric approach. Biometrics 1988;44:837-45
38. Seed PT, Tobias A. Summary statistics for diagnostic tests. Stata J 2004;4:490
39. Hawass NE. Comparing the sensitivities and specificities of two diagnostic procedures performed on the same group of patients. Br J Radiol 1997;70:360-6
40. Holle JU, Herrmann K, Gross WL, Csernok E. Comparative analysis of different commercial ELISA systems for the detection of anti-neutrophil cytoplasm antibodies in ANCA-Associated vasculitides. Clin Exp Rheumatol 2012;30(Suppl 70):S66-9
41. Hagen EC, Daha MR, Hermans J, Andrassy K, Csernok E, Gaskin G, et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int 1998;53:743-53